09 December 2025
09 December 2025
Experts said that US public health is now at risk after the CDC vaccine panel voted against the widespread recommendation for the hepatitis B vaccine at birth.
The decision is based on outcomes from the Phase II NOBILITY and Phase III REGENCY trials.
The ARPA-H CATALYST programme aims to transform preclinical drug safety prediction using human-based models.
The deal is anticipated to be finalised in the first quarter of 2026, pending the fulfilment of all closing conditions.
The partnership is intended to expedite R&D in small and large-molecule analysis.
Opinions were divided on the continued use of the hepatitis B vaccine in a paediatric population.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
